Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.

The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc (2012) 3.45

Sexual activity and function among middle-aged and older men and women with hypertension. J Hypertens (2013) 2.14

A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Neth Heart J (2014) 0.93

Nitric oxide-mediated coronary flow regulation in patients with coronary artery disease: recent advances. Int J Angiol (2011) 0.90

Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. Int J Hypertens (2012) 0.87

Let's talk about sex : (title of a song from 1991 by 'Salt 'n Pepa'). Neth Heart J (2013) 0.82

Changes in erectile dysfunction over time in relation to Framingham cardiovascular risk in the Boston Area Community Health (BACH) Survey. J Sex Med (2014) 0.80

Management of erectile dysfunction in hypertension: Tips and tricks. World J Cardiol (2014) 0.80

Does vitamin D deficiency contribute to erectile dysfunction? Dermatoendocrinol (2012) 0.79

Should patients with erectile dysfunction be evaluated for cardiovascular disease? Asian J Androl (2011) 0.79

Validation of the International Index of Erectile Function (IIFE) for use in Brazil. Arq Bras Cardiol (2013) 0.78

Erectile dysfunction and CVD. Nat Rev Cardiol (2010) 0.77

Erectile dysfunction and its management in patients with diabetes mellitus. Rev Endocr Metab Disord (2015) 0.76

Uric acid level and erectile dysfunction in patients with coronary artery disease. J Sex Med (2013) 0.76

Facts and ideas from anywhere. Proc (Bayl Univ Med Cent) (2010) 0.75

Dietary flavonoid intake and incidence of erectile dysfunction. Am J Clin Nutr (2016) 0.75

Erectile dysfunction and cardiovascular disease. Arab J Urol (2013) 0.75

Long-term treatment of clonidine, atenolol, amlodipine and dihydrochlorothiazide, but not enalapril, impairs the sexual function in male spontaneously hypertensive rats. PLoS One (2015) 0.75

Preoperative erectile function and the pathologic features of prostate cancer. Int Braz J Urol (2015) 0.75

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? Am J Cardiovasc Drugs (2016) 0.75

Erectile dysfunction: A present day coronary disease risk equivalent. Indian J Med Res (2016) 0.75

Erectile dysfunction and CVD. Nat Rev Urol (2010) 0.75

Evaluation of high sensitive troponin in erectile dysfunction. Dis Markers (2015) 0.75

Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart (2017) 0.75

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17

Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (2011) 13.10

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69

Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 9.01

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med (2003) 7.74

Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35

Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 6.68

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 6.55

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16

Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet (2011) 5.95

Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47

Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24

Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 5.19

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 4.99

Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91

Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med (2014) 4.88

Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86

Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74

Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet (2007) 4.74

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73

Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68